Search results
LEO Pharma reports positive data from Phase III plaque psoriasis trial
Clinical Trials Arena via Yahoo Finance· 2 days agoA total of 604 patients across 39 sites in China participated in the study. The primary goal of the...
IPC Develops Consensus on Generalized Pustular Psoriasis
Medscape· 2 days agoThe IPC's definition and diagnostic criteria for GPP minimized the complexity of clinical...
Psoriasis Skin Care Guide | Healthline
Healthline· 7 days agoYour skin care routine matters when it comes to relieving painful, itchy patches of inflamed skin in psoriasis. Knowing how to care for psoriasis skin —...
6 Psoriasis Home Remedies to Try
Healthline· 7 days agoThis means no home remedy can completely relieve your symptoms with a guarantee they won’t return someday. Psoriasis can be very unique to each...
Amjevita and dosage: Strengths, forms, how to inject, and more
Medical News Today· 6 days agoAmjevita comes as a solution subcutaneous injection. Your doctor will determine the best dosage to...
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
InvestorPlace· 2 days agoInvestors concerned about broader market undulations may want to consider the resilience narrative...
VYNE Therapeutics receives FDA approval for trial of VYN202
Clinical Trials Arena via Yahoo Finance· 3 days agoThe company expects to report top-line results from the SAD/MAD...optimal oral bioavailability. VYNE...
5 Best Undervalued Stocks To Buy In May 2024
Forbes· 18 hours agoResearching undervalued stocks? We examined stocks to identify the top undervalued stocks in May 2024. Dive into the results here.
Siliq and cost: Reducing long-term drug costs and more
Medical News Today· 6 days agoSiliq’s cost with and without insurance can depend on several factors, such as whether Siliq has a...
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Digital Journal· 2 days agoEntered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1]Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials ...